- Home
- AU vs TFX Comparison
AU vs TFX Comparison
Compare AU & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- TFX
- Stock Information
- Founded
- AU 1944
- TFX 1943
- Country
- AU United States
- TFX United States
- Employees
- AU N/A
- TFX N/A
- Industry
- AU Precious Metals
- TFX Medical/Dental Instruments
- Sector
- AU Basic Materials
- TFX Health Care
- Exchange
- AU Nasdaq
- TFX Nasdaq
- Market Cap
- AU 10.3B
- TFX 9.0B
- IPO Year
- AU 1972
- TFX N/A
- Fundamental
- Price
- AU $25.75
- TFX $183.26
- Analyst Decision
- AU Hold
- TFX Buy
- Analyst Count
- AU 5
- TFX 9
- Target Price
- AU $31.75
- TFX $259.00
- AVG Volume (30 Days)
- AU 4.5M
- TFX 435.1K
- Earning Date
- AU 11-07-2024
- TFX 10-31-2024
- Dividend Yield
- AU 0.85%
- TFX 0.74%
- EPS Growth
- AU N/A
- TFX N/A
- EPS
- AU 1.34
- TFX 5.03
- Revenue
- AU $5,299,000,000.00
- TFX $3,025,824,000.00
- Revenue This Year
- AU $31.43
- TFX $4.52
- Revenue Next Year
- AU $21.09
- TFX $4.92
- P/E Ratio
- AU $20.24
- TFX $36.46
- Revenue Growth
- AU 17.78
- TFX 2.27
- 52 Week Low
- AU $15.80
- TFX $182.80
- 52 Week High
- AU $32.57
- TFX $257.85
- Technical
- Relative Strength Index (RSI)
- AU 49.20
- TFX 30.98
- Support Level
- AU $24.85
- TFX $182.80
- Resistance Level
- AU $27.22
- TFX $188.87
- Average True Range (ATR)
- AU 0.67
- TFX 4.30
- MACD
- AU 0.24
- TFX 0.71
- Stochastic Oscillator
- AU 48.60
- TFX 3.64
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.